Pickersgill, T.

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

Cossburn, M., Pace, A. A., Jones, J., Ali, R., Ingram, G., Baker, K., Hirst, C., Zajicek, J., Scolding, N., Boggild, M., et al. (2011) · Neurology

Multiple Sclerosis Research StudiesAutoimmune Neurological Disorders and Treatments

Cited by 216

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Marson, A., Burnside, G., Appleton, R., Smith, D., Leach, J. P., Sills, G., Tudur-Smith, C., Plumpton, C., Hughes, D. A., Williamson, P., et al. (2021) · The Lancet

Epilepsy research and treatmentPharmacological Effects and Toxicity Studies

Cited by 208

Multiple sclerosis relapses and depression

Moore, P., Hirst, C., Harding, K. E., Clarkson, H., Pickersgill, T. P., & Robertson, N. P. (2012) · Journal of Psychosomatic Research

Multiple Sclerosis Research StudiesCancer survivorship and care

Cited by 80

The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic

Tallantyre, E. C., Causon, E. G., Harding, K. E., Pickersgill, T. P., & Robertson, N. P. (2015) · Multiple Sclerosis Journal

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 18